Zepbound Hair Loss & Telogen Effluvium: Honest Evidence Review

Zepbound hair loss is one of the most-searched concerns for adults starting Lilly’s obesity drug, and the honest read of the evidence is more reassuring than the search-suggest results imply. The Zepbound prescribing information^[3] lists alopecia in roughly 5% of Zepbound 15 mg patients in SURMOUNT-1 versus ~1% on placebo across 72 weeks — a slightly higher rate than the 3.3% reported for Wegovy 2.4 mg in STEP-1^[5], and exactly what you’d predict from the larger weight- loss magnitude Zepbound produces (mean −20.9% total body weight at 15 mg in SURMOUNT-1 vs −14.9% on Wegovy in STEP-1)^[1]. The Mounjaro label^[4] — same molecule, type-2-diabetes dose tier — does not list alopecia in its main clinical-trial adverse-event table, mirroring the same dose-response pattern seen across the semaglutide family. The clinically useful framing is the one a dermatologist would give you: this is telogen effluvium — the same temporary shedding pattern that follows pregnancy, bariatric surgery, severe COVID, high fever, major surgery, and any other rapid weight-loss episode^[6][7]. It is not direct drug toxicity, it is not scarring, it is not permanent, and it resolves on its own within 6-12 months as weight stabilizes.

The honest short answer for Zepbound patients

Zepbound is tirzepatide approved by the FDA for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, obstructive sleep apnea). In December 2024 the FDA also approved Zepbound for adults with obesity and moderate-to-severe obstructive sleep apnea (the SURMOUNT-OSA program). Across these indications, the alopecia signal comes overwhelmingly from one trial — SURMOUNT-1 — and one dose — 15 mg, the maintenance dose that drives the biggest weight loss.

The Zepbound prescribing information^[3] reports alopecia in roughly 5% of patients on Zepbound 15 mg in SURMOUNT-1 versus ~1% on placebo over 72 weeks. That is a real, dose- dependent signal, and it is more than the Wegovy 2.4 mg rate (3.3% in STEP-1)^[5]. But it is NOT the signature of a drug poisoning your hair follicles. It is the signature of your body reacting to losing ~21% of its weight over 18 months — the same signature you would see after gastric bypass, after childbirth, or after a 4-week ICU stay.

What the Zepbound FDA label and SURMOUNT-1 actually reported

SURMOUNT-1^[1] is the 72-week pivotal trial that earned Zepbound its obesity indication. 2,539 adults with BMI ≥30 (or ≥27 with weight-related comorbidity) were randomized 1:1:1:1 to tirzepatide 5 mg, 10 mg, 15 mg, or placebo. Mean weight reduction at 72 weeks was −15.0% at 5 mg, −19.5% at 10 mg, and −20.9% at 15 mg — versus −3.1% on placebo. That −20.9% headline is the largest mean TBWL ever reported in a phase-3 trial of an FDA-approved chronic-weight-management drug.

Alopecia rates in the SURMOUNT-1 adverse-event tables scale with dose. The Zepbound DailyMed label^[3] reports the all-cause alopecia incidence at approximately ~5% on Zepbound 15 mg versus ~1% on placebo. Mid-tier doses (5 mg and 10 mg) report lower rates — consistent with their smaller weight-loss magnitudes. The sex skew is striking and matches every other obesity drug in the literature: women report alopecia at meaningfully higher rates than men, mirroring the well-established female predominance of telogen effluvium in dermatology cohorts^[6].

SURMOUNT-4^[2] added a second piece of the picture: after a 36-week open-label lead-in on tirzepatide 15 mg (mean weight reduction −20.9% in this lead-in cohort), 670 adults were randomized to continue tirzepatide 15 mg or switch to placebo for an additional 52 weeks. The continued-tirzepatide group lost a further −5.5% body weight; the placebo-switch group regained +14.0%. The practical implication for hair: the body-weight stabilization that ends a telogen- effluvium episode does NOT require stopping Zepbound. Continued therapy at a stable weight is the better path; stopping triggers regain that may itself be a new physiologic stressor.

The mechanism is rapid weight loss, not direct drug toxicity

The clinical syndrome behind every “Zepbound made my hair fall out” complaint is telogen effluvium — the textbook hair-cycle disturbance described in the Hughes, Syed & Saleh StatPearls chapter^[6] that every dermatology resident reads. Normal scalp hair cycles through three phases: anagen (growing, 2-7 years), catagen (regressing, ~2-3 weeks), and telogen (resting/shedding, ~3 months). At baseline, roughly 85-90% of follicles are in anagen and 10-15% are in telogen. A systemic stressor — rapid weight loss, childbirth, high fever, major surgery, severe illness, crash dieting — can synchronize a large fraction of follicles into telogen at the same time. Three months later, those follicles shed simultaneously, producing the sudden noticeable increase in hair on the pillow, in the shower drain, and in the brush.

Three features distinguish telogen effluvium from the more worrying patterns:

• Diffuse, not patchy. Hair thins evenly across the entire scalp. Discrete bald patches point toward alopecia areata (autoimmune) and need a different workup^[6].
• Non-scarring. The follicles are still alive and structurally intact — they have just paused. A scarring alopecia (red, painful, or shiny smooth patches) destroys the follicle permanently and needs a dermatology biopsy.
• Self-limiting. When the systemic stressor resolves, the follicles re-enter anagen and regrow. Recovery is the rule, not the exception^[6].

The mechanism is not tirzepatide binding to a hair-follicle receptor and killing keratinocytes. There is no evidence in the published GIP/GLP-1 receptor pharmacology literature for a direct toxic effect on the hair shaft or the dermal papilla — neither receptor is expressed on the hair follicle in any clinically meaningful density. The mechanism is the rapid drop in caloric intake, the temporary protein deficit during the first weeks of severe appetite suppression, and the lean-mass loss that accompanies any rapid weight reduction^[8] — collectively a textbook telogen-effluvium trigger by any standard definition^[6][7].

The Kang 2024 single-center retrospective^[7] of telogen effluvium specifically tied to weight loss (no GLP-1 exposure in the cohort) documented the same timing signature and the same self-limiting recovery course observed in Zepbound patients — reinforcing that the mechanism is the weight loss itself, not the drug.

Why Zepbound’s alopecia rate exceeds Wegovy’s

Across the published labels the pattern is consistent: Zepbound’s reported alopecia rate at the maximum obesity dose (~5% at 15 mg) is roughly 1.5x the Wegovy 2.4 mg rate (3.3%), and the gap aligns with the weight- loss magnitude difference (~21% vs ~15% TBWL). This is not a property of receptor pharmacology — tirzepatide is a dual GIP/GLP-1 agonist and semaglutide is a GLP-1 monoagonist, but neither binds receptors on hair follicles. The difference is a property of how much weight each drug drives off in how much time: Zepbound’s mean −20.9% TBWL at 72 weeks exceeds Wegovy’s mean −14.9% TBWL at 68 weeks^[1][5], and the larger rapid weight-loss episode synchronizes more follicles into telogen.

Mechanistic interpretation: more rapid weight loss synchronizes a larger fraction of hair follicles into telogen. If you lose 15% of body weight over 68 weeks, the systemic-stress signal is large; if you lose 21% over 72 weeks, the signal is larger still. Faster rate-of-loss and larger absolute magnitude both contribute, and Zepbound drives more of both. None of this implies Zepbound is somehow worse for hair as a molecule — it is the weight loss it produces that drives the signal, and patients losing the same magnitude of weight via bariatric surgery or very-low-calorie diet would show the same rate.

Why Mounjaro at T2D doses doesn’t list alopecia

Mounjaro is the same molecule (tirzepatide) at the same dose strengths (2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg) approved for type 2 diabetes. Yet the Mounjaro DailyMed label^[4] does not list alopecia in the main clinical-trial adverse-event tables of the SURPASS T2D program. Why?

The SURPASS trials reported mean TBWL of roughly 7-13% at maximum dose in adults with type 2 diabetes — substantially less than the ~21% seen at Zepbound 15 mg in SURMOUNT-1. The trial populations are different (T2D vs obesity-without-T2D), average baseline BMI is different, mean dose exposure is different, and the absolute weight-loss magnitude is far smaller. At that lower magnitude the telogen-effluvium trigger is weaker, the alopecia signal in the AE tables falls below the threshold of statistical significance vs placebo, and the FDA label reflects that. The pattern exactly mirrors what we see with Ozempic vs Wegovy: the Ozempic T2D label lists alopecia only in postmarketing experience, not in the main clinical-trial AE table.

The practical takeaway: the alopecia rate tracks the weight-loss magnitude, not the brand or the indication. Same molecule, different label sections, different rates, same underlying mechanism. See the Mounjaro vs Zepbound disambiguation for more on why the same active ingredient is sold under two brand names with two different indications.

Timeline: when it starts, peaks, and resolves

Telogen effluvium has a remarkably consistent timing signature that’s useful for setting expectations on Zepbound:

• Weeks 0-8: dose titration (2.5 mg → 5 mg → 7.5 mg per the FDA-mandated 4-week escalation). Rapid appetite suppression and a sharp drop in caloric intake. No visible hair changes yet — the follicles are shifting into telogen but have not shed yet.
• Months 2-3: first shedding episode. Roughly 8-12 weeks after the rapid-weight-loss trigger, the synchronized telogen cohort sheds. Patients notice more hair on the pillow, in the shower drain, and in the brush. This is the classic delayed onset of telogen effluvium^[6].
• Months 3-6: peak shedding. The most dramatic phase, often coinciding with the maintenance- dose plateau at 16-20 weeks (when most patients reach 10 mg or 15 mg). Daily shed counts can double or triple normal baseline.
• Months 6-12: spontaneous resolution. As weight stabilizes (the typical SURMOUNT-1 weight- loss curve plateaus around month 12-16), the telogen cohort completes its cycle and new anagen hairs regrow. Regrowth is visible first as short bristly new hairs along the hairline and part line.
• Months 12-18: full recovery for most patients. Hair density returns to the pre-treatment baseline, though the regrown hairs may take 2+ years to reach their previous length given the ~1 cm/month average hair-growth rate.

For a week-by-week visualization of how alopecia overlaps with the other GLP-1 side effects, the GLP-1 side-effect timeline tool plots each side effect against the SURMOUNT-1 dose- titration calendar.

Same mechanism as post-pregnancy, post-bariatric, post-COVID hair loss

The single most useful reframe for an anxious Zepbound patient is this: the hair loss you’re experiencing is biochemically identical to what happens 3 months after giving birth, 3 months after bariatric surgery, and 3 months after a severe COVID infection or hospitalization. Every one of those scenarios shares the same mechanism — a sudden systemic stressor synchronizes the hair cycle — and every one of those scenarios shows the same timing signature and the same self-limiting recovery curve^[6].

Bariatric surgery patients in particular show a near- universal telogen-effluvium episode 3-6 months after Roux-en-Y gastric bypass or sleeve gastrectomy. The dermatology literature on this is well-established and the patient counseling is identical: it is expected, it is temporary, focus on protein and micronutrient adequacy, and the hair grows back. Post-pregnancy telogen effluvium (often called “postpartum hair loss”) is recognized as so common — affecting 40-50% of new mothers — that obstetricians routinely warn patients about it during prenatal visits. The COVID-19 pandemic produced a wave of telogen effluvium 3 months after infection that briefly made dermatology headlines^[6] and followed the same playbook.

For a Zepbound patient, the “Zepbound caused my hair loss” framing is technically true in the sense that Zepbound enabled the rapid weight loss that triggered the telogen shift — but the same hair loss would occur from any other weight-loss intervention producing the same magnitude of TBWL over the same timeframe. Patients losing 20% of body weight via surgery or very-low-calorie diets report the same hair-shedding pattern.

Practical mitigation: protein, micronutrients, honest biotin assessment

Three nutritional interventions have actual evidence behind them for supporting hair during rapid weight loss. None are a hair-loss treatment in the FDA sense — they support the underlying physiology so the telogen-effluvium episode runs its natural course without being prolonged by frank micronutrient deficiency.

Protein: 1.2-1.6 g/kg lean body mass per day

The Look 2025 DXA body-composition analysis of SURMOUNT-1^[8] demonstrated that Zepbound patients lost roughly 10% of their lean body mass alongside the headline ~21% TBWL — meaning about one-quarter of the weight lost was lean tissue, not fat. Hair follicles are protein-synthesis-intensive (the hair shaft is ~90% keratin), and inadequate dietary protein during rapid weight loss is a recognized contributor to telogen-effluvium severity^[6].

The evidence-based target for adults on GLP-1 or GIP/GLP-1 therapy is 1.2-1.6 g of protein per kg of lean body mass per day. For a 200 lb patient with ~30% body fat (lean mass ~63 kg), that translates to roughly 75-100 g of protein per day — meaningfully higher than the 0.8 g/kg RDA used for sedentary adults at weight maintenance. Practical sources: 4-6 oz of cooked salmon (28-42 g), Greek yogurt (15-17 g per cup), eggs (6 g each), tuna (25 g per 3-oz can), chicken breast (26 g per 3 oz), cottage cheese (24 g per cup), and whey or plant-based protein powders (20-25 g per scoop) when whole-food intake is appetite-suppressed below target. The GLP-1 protein calculator builds the daily gram target directly from these parameters.

Iron and ferritin: get a lab panel before supplementing

The Durusu Turkoglu 2024 J Cosmet Dermatol cohort^[11] examined biochemical status in telogen-effluvium patients across hemoglobin, ferritin, B12, vitamin D, thyroid function, zinc, copper, biotin, and selenium. Iron deficiency — specifically low ferritin (the iron storage protein) — is the most- replicated micronutrient deficiency tied to telogen effluvium in the literature. Women with menstrual blood loss are at higher baseline risk, and the sex skew in alopecia reporting rates across both the Wegovy and Zepbound labels is partly attributable to this.

A reasonable lab panel for a Zepbound patient with new shedding includes: CBC, ferritin, iron + TIBC, 25-hydroxyvitamin D, B12, TSH. The threshold for ferritin supplementation in the dermatology literature is often cited as <30 ng/mL for symptomatic patients (vs the standard lab-reported “normal” range starting at ~10-15 ng/mL). If labs are abnormal, treat the deficiency — iron orally with vitamin C for absorption, vitamin D 1,000-2,000 IU daily, B12 if borderline-low (especially if the patient is on metformin alongside Zepbound, which impairs B12 absorption). Do not start empiric iron supplementation without labs — iron overload is also harmful.

Biotin overhype — what the evidence actually shows

The supplement aisle is full of biotin-branded hair- growth products marketed at 5,000-10,000 mcg per dose — roughly 170-330 times the 30 mcg adequate intake. The Patel, Swink & Castelo-Soccio 2017 Skin Appendage Disorders review^[9] systematically examined the evidence and reached a clear conclusion: biotin supplementation in non-deficient patients does not improve hair growth. The studies showing benefit were either in patients with verified biotin deficiency (rare, typically caused by inborn errors of metabolism or prolonged raw-egg-white ingestion) or in combination formulations where biotin was bundled with actual active ingredients.

The Trüeb 2018 follow-up comment^[10] in the same journal reinforced the point: the marketing claims for high-dose biotin are not supported by controlled clinical evidence in immunocompetent adults eating a standard Western diet. The Durusu Turkoglu 2024 cohort^[11] specifically measured biotin levels in telogen-effluvium patients and did not find a deficiency pattern driving the syndrome.

One important practical harm every Zepbound patient should know: biotin at 5,000+ mcg doses interferes with immunoassay-based laboratory tests — including thyroid function tests, troponin (the cardiac biomarker used in emergency departments to evaluate chest pain), and several hormone assays. The FDA has issued safety communications about falsely-low TSH and falsely-elevated free T4 results in patients on high-dose biotin, leading to misdiagnosis of hyperthyroidism. If you take biotin, stop it at least 72 hours before any bloodwork and tell your clinician.

Bottom line on biotin: it doesn’t work for non- deficient adults, it interferes with critical lab tests, and the money is better spent on a protein source.

Vitamin D, zinc, and selenium: cover the basics

Vitamin D deficiency is independently common in patients with obesity and is associated with telogen effluvium in the Durusu Turkoglu cohort^[11]. Most US adults benefit from 1,000-2,000 IU daily, particularly during winter months and for patients with limited sun exposure. Zinc and selenium adequacy is best achieved through a varied diet rather than high-dose supplementation — excess zinc can paradoxically cause hair loss and excess selenium is frankly toxic.

When to call your prescriber or a dermatologist

Most Zepbound-related hair shedding is telogen effluvium and runs its natural course without medical intervention. The situations that do warrant a call to your prescriber or a dermatology referral:

• Patchy loss with discrete circular bald spots — suggests alopecia areata, an autoimmune condition that needs intralesional steroid injections or topical immunotherapy^[6].
• Scarring patches — red, painful, shiny, or smooth areas where the follicular openings have disappeared. This suggests a scarring alopecia (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia) and needs a punch biopsy for diagnosis — treatment within months matters because scarring is permanent.
• Receding hairline or crown thinning in a male pattern — suggests androgenetic alopecia (male-pattern or female-pattern hair loss), which is treatable with finasteride, minoxidil, or low- level laser therapy. This may be unmasked by but is not caused by Zepbound.
• Shedding lasting beyond 12 months after weight has stabilized — suggests chronic telogen effluvium or an unaddressed underlying driver (iron deficiency, thyroid disease, autoimmune disease).
• Associated symptoms — weight loss continuing beyond the expected SURMOUNT-1 curve, fatigue, cold intolerance, or palpitations — warrant a TSH and basic workup to rule out thyroid disease.

For the broader landscape of Zepbound side effects and how they evolve over the first year, see the GLP-1 side effect Q&A hub and the Zepbound vs Wegovy side-effects head-to-head.

FAQ

How common is hair loss on Zepbound?

Roughly 5% of patients on Zepbound 15 mg in SURMOUNT-1 reported alopecia, versus ~1% on placebo over 72 weeks^[3]. Mid-tier doses (5 mg and 10 mg) report lower rates, consistent with their smaller weight- loss magnitudes. Rates are higher in women than men, mirroring the well-established female predominance of telogen effluvium in the dermatology literature.

Will my hair grow back after stopping Zepbound?

Yes. For telogen effluvium — the syndrome causing Zepbound-attributed hair loss — spontaneous regrowth is the rule. Recovery typically takes 6-12 months after weight stabilizes, regardless of whether you continue or stop the medication. Stopping Zepbound is not required for regrowth and may not even be beneficial: SURMOUNT-4^[2] showed that withdrawal leads to ~14% weight regain within a year, which is itself a metabolic stressor.

Does Zepbound itself contain anything that damages hair?

No. There is no published evidence for a direct toxic effect of tirzepatide on hair follicles, hair shafts, or the dermal papilla — and neither GIP nor GLP-1 receptors are expressed on hair follicles in any clinically meaningful density. The mechanism is indirect: rapid weight loss synchronizes the hair cycle into a temporary telogen shedding phase, the same mechanism seen after pregnancy, bariatric surgery, and severe COVID.

Why is Zepbound’s alopecia rate higher than Wegovy’s?

Because Zepbound drives larger and faster weight loss. SURMOUNT-1 reported mean −20.9% TBWL at 15 mg vs −14.9% on Wegovy 2.4 mg in STEP-1, and the alopecia rate (~5% vs 3.3%) tracks the weight-loss magnitude. Zepbound is not worse for hair as a molecule; it produces a stronger systemic-stressor signal for telogen-effluvium synchronization.

Does Mounjaro cause hair loss too?

Mounjaro (tirzepatide at the type-2-diabetes dose tier) did not surface alopecia in the main clinical-trial adverse-event tables of the SURPASS trials or its DailyMed label^[4]. The SURPASS trials reported mean TBWL of roughly 7-13% — substantially less than the ~21% seen at Zepbound 15 mg in SURMOUNT-1, and at that lower magnitude the telogen-effluvium trigger falls below the AE-table threshold. Same molecule, same dose strengths, different patient populations, different labels.

When does Zepbound hair loss start and end?

Shedding typically begins 2-3 months after rapid weight- loss onset, peaks at months 3-6 (often coinciding with the maintenance-dose plateau at 16-20 weeks when most patients are at 10 mg or 15 mg), and resolves spontaneously within 6-12 months as weight stabilizes. Full hair density usually returns within 12-18 months.

Should I take biotin?

Probably not. The Patel 2017 review^[9] found no benefit for biotin supplementation in non-deficient adults, and high-dose biotin interferes with thyroid and cardiac lab tests. Spend the money on a protein source instead.

Should I get bloodwork?

Yes — CBC, ferritin, 25-hydroxyvitamin D, B12, and TSH at minimum. Iron deficiency is the most-replicated micronutrient driver of telogen effluvium and is treatable. Do not start empiric iron supplementation without confirming the deficiency.

Will switching from Zepbound to Wegovy or Ozempic stop the hair loss?

Not reliably — the mechanism is rapid weight loss, not the specific drug, so all GLP-1 and dual-agonist weight-loss medications carry the same telogen-effluvium risk. Wegovy at the 2.4 mg dose has a slightly lower reported rate (3.3%) because it drives slightly slower and smaller weight loss; Ozempic at the lower T2D dose tier lists alopecia only in its postmarketing experience section. Switching during an active telogen-effluvium episode may slow the rate of additional shedding if it also slows the rate of weight loss, but it will not reverse hair that has already entered telogen.

Related research and tools

• The tirzepatide molecule-level sister article covers the same telogen-effluvium pattern across both Zepbound (obesity) and Mounjaro (T2D) indications and the dose-response evidence base.
• The Ozempic / Wegovy hair-loss evidence review covers the same pattern with STEP-1 and SUSTAIN-1 evidence and the lower-magnitude weight-loss comparison.
• The parent guide to GLP-1 fatigue and hair loss duration covers the same hair-loss pattern across the full GLP-1 class.
• The GLP-1 side effect Q&A hub for the most-asked patient questions across the side- effect landscape.
• Zepbound vs Wegovy side-effects head-to-head for the full AE-table comparison across both pivotal trials.
• Resistance training to preserve lean mass on GLP-1s — the strongest non-nutritional lever for limiting lean-mass loss during rapid weight reduction.
• Interactive GLP-1 side-effect timeline tool to see when each side effect peaks and resolves by drug and week.
• GLP-1 protein calculator for a personalized daily protein target.